Bioatla provides clinical program updates and upcoming 2023 milestones

San diego, jan. 10, 2023 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced its recent accomplishments for its clinical pipeline and provided upcoming 2023 milestones. company updates and 2023 milestones will be presented in a fireside chat at 41st annual j.p. morgan healthcare conference, january 10, 2023.
BCAB Ratings Summary
BCAB Quant Ranking